Drug Profile
Quilizumab
Alternative Names: Anti M1 prime monoclonal antibody; MEMP-1972A; RG-7449Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Genentech
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Immunoglobulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma; Allergic rhinitis; Chronic urticaria
Most Recent Events
- 28 Jan 2015 Discontinued - Phase-II for Chronic urticaria (Treatment-resistant) in Germany, Canada (SC)
- 28 Jan 2015 Discontinued - Phase-I for Allergic rhinitis in Canada (Parenteral)
- 28 Jan 2015 Discontinued - Phase-II for Allergic asthma (Prevention) in Canada (IV)